Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mirvetuximab soravtansine + bevacizumab
- Development stage
- Unknown
- Lead developer
- ImmunoGen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Mirvetuximab soravtansine + bevacizumab is a combination therapy under investigation for the treatment of recurrent ovarian cancer and related gynecologic malignancies. Mirvetuximab soravtansine is an antibody-drug conjugate (ADC) that targets folate receptor alpha (FRα) on tumor cells. It consists of a humanized monoclonal antibody linked to the cytotoxic agent DM4 (a maytansinoid), which disrupts microtubule function and induces cell death in FRα-expressing cancer cells. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis required for tumor growth. The combination has shown promising antitumor activity and durable responses in patients with high FRα-expressing recurrent ovarian cancer who have progressed after platinum-based chemotherapy[2][3][5][8].
- Brand names
- ElahereAvastin
- Other names
- mirvetuximab soravtansine-gynx
02
Targets
Beyond the preview
Go deeper on mirvetuximab soravtansine + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mirvetuximab soravtansine + bevacizumab.